Optceutics Ltd has developed an innovative ocular model (PK-Eye) to accelerate ophthalmic drug development of protein-based and small molecules for the posterior segment of the eye. The PK-Eye is a two-compartment model that mimics the dimensions, mass transfer, aqueous outflow and clearance from the posterior segment. It has shown utility for (i) the rapid and accurate evaluation of proprietary third party formulations and (ii) accelerating pre-formulation studies for new intraocular medicines. The PK-Eye is used to potentially avoid non-human primate studies (especially for biosimilar development) and to design clinical protocols at the most appropriate dose are paramount for clinical development.